Abstract
Using retrospectively collected outcome data for treatment naïve subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN β) (n=424), we replicated the lack of a significant difference in efficacy between these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1 1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN β treated subjects.
Copyright © 2010 Elsevier B.V. All rights reserved.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Drug Resistance / genetics
-
Drug Resistance / immunology
-
Female
-
Glatiramer Acetate
-
HLA-DR Antigens / genetics*
-
HLA-DRB1 Chains
-
Humans
-
Interferon Regulatory Factors / genetics
-
Interferon-beta / pharmacology
-
Interferon-beta / therapeutic use
-
Male
-
Middle Aged
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / genetics
-
Multiple Sclerosis / immunology*
-
Peptides / pharmacology
-
Peptides / therapeutic use
-
Retrospective Studies
Substances
-
HLA-DR Antigens
-
HLA-DRB1 Chains
-
HLA-DRB1*15:01 antigen
-
Interferon Regulatory Factors
-
Peptides
-
interferon regulatory factor-8
-
Glatiramer Acetate
-
Interferon-beta